Primary myelofibrosis
Also known as: PMF, Chronic idiopathic myelofibrosis, Agnogenic myeloid metaplasia, Primary osteomyelofibrosis
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterised by clonal marrow fibrosis, resulting in extramedullary haematopoiesis, systemic inflammation, and potential transformation to acute leukaemia. Clinical manifestations include anaemia, profound fatigue, splenomegaly, and constitutional symptoms, necessitating multidisciplinary management by specialist haematologists. Traditional Chinese Medicine functions exclusively as an individualised supportive adjunct to conventional pharmacological therapy, transfusion support, and stem cell transplantation. Current literature addresses acupuncture in a general context but lacks PMF-specific efficacy data; similarly, research focuses on molecular mechanisms rather than clinical TCM outcomes. Neither acupuncture nor herbal medicine is established as a therapeutic modality for marrow fibrosis or reversing drug resistance. The TCM patterns outlined provide traditional symptomatic frameworks and do not constitute diagnostic categories or demonstrate antineoplastic benefit.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Prioritise tolerable, nutrient-dense meals; consult a dietitian if experiencing weight loss or early satiety.
- •Maintain gentle physical activity within haematology advice, avoiding contact sports and abdominal impact in the presence of splenomegaly.
- •Maintain a symptom and medication log covering fatigue, sleep, appetite, bleeding, and temperature during periods of illness.
- •Establish consistent sleep hygiene and adhere strictly to specialist protocols regarding immunisation, infectious disease prophylaxis, and food safety standards.
Cautions & Contraindications
- •Defer needling with active bleeding, clinically significant thrombocytopenia, severe neutropenia or acute infection until haematology clearance. Use current blood counts and local oncology protocols; the supplied review does not establish numerical safety thresholds.[]
- •Do not needle over an enlarged spleen, unexplained abdominal mass, infected skin, bruising, vascular access devices or recent procedure sites. Avoid deep abdominal or thoracic needling. These are conservative procedural precautions, not PMF trial findings.[]
- •Do not start herbs or supplements without a complete medicine review and agreement from the treating team, especially with anticoagulants, antiplatelets or JAK inhibitors. Do not stop prescribed therapy to trial TCM; the integrative review supports adjunctive rather than replacement care.[]
- •Avoid bloodletting, wet cupping and vigorous scraping where bleeding risk exists. Pregnancy and transplantation require specialist coordination before needling or herbs; the supplied abstracts establish no safety evidence for these groups.[]
When to reassess or seek care again
Before treatment, document current haematology advice, blood counts, medicines and baseline fatigue, sleep and appetite scores on 0–10 scales. Review after 2–4 weeks or 2–4 supportive sessions, recording adverse effects and functional change. Stop or modify care if there is no meaningful symptom benefit. New bleeding, fever, worsening abdominal symptoms or declining function requires earlier medical review; blood-count changes and progression assessment remain the haematology team's responsibility.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Genes & genomics · 2026
- British journal of haematology · 2026
- Journal of pharmaceutical and biomedical analysis · 2026
- Journal of clinical medicine · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
